May 2020—Ortho Clinical Diagnostics announced the FDA granted emergency use authorization to its second COVID-19 antibody test—the Vitros Immunodiagnostic Products Anti-SARS-CoV-2 IgG Test. The test demonstrated 100 percent specificity and runs on Ortho’s high-throughput, fully automated analyzers including its Vitros XT 7600 integrated system, Vitros 3600 immunodiagnostic system, Vitros 5600 integrated system, and it will soon be available on Vitros ECi/ECiQ immunodiagnostic systems.
The company’s first antibody test, the Vitros Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack, detects antibodies (including IgG and IgM) to SARS-CoV-2. It runs on the Vitros XT 7600, Vitros 3600, Vitros 5600, and Vitros ECi/ECiQ systems, which can process about 150 tests an hour.
Ortho Clinical Diagnostics, 800-421-3311